Abstract

The RIG-I-like receptors (RLRs) play a major role in sensing RNA virus infection to initiate and modulate antiviral immunity. They interact with particular viral RNAs, most of them being still unknown. To decipher the viral RNA signature on RLRs during viral infection, we tagged RLRs (RIG-I, MDA5, LGP2) and applied tagged protein affinity purification followed by next-generation sequencing (NGS) of associated RNA molecules. Two viruses with negative- and positive-sense RNA genome were used: measles (MV) and chikungunya (CHIKV). NGS analysis revealed that distinct regions of MV genome were specifically recognized by distinct RLRs: RIG-I recognized defective interfering genomes, whereas MDA5 and LGP2 specifically bound MV nucleoprotein-coding region. During CHIKV infection, RIG-I associated specifically to the 3' untranslated region of viral genome. This study provides the first comparative view of the viral RNA ligands for RIG-I, MDA5 and LGP2 in the presence of infection.

Article and author information

Author details

  1. Raul Y Sanchez David

    Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Chantal Combredet

    Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Odile Sismeiro

    Transcriptome and Epigenome, BioMics Pole, Center for Innovation and Technological Research, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Marie-Agnès Dillies

    Transcriptome and Epigenome, BioMics Pole, Center for Innovation and Technological Research, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Bernd Jagla

    Transcriptome and Epigenome, BioMics Pole, Center for Innovation and Technological Research, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Jean-Yves Coppée

    Transcriptome and Epigenome, BioMics Pole, Center for Innovation and Technological Research, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Marie Mura

    Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Mathilde Guerbois Galla

    University of Texas Medical Branch, Galveston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Philippe Despres

    Technology platform CYROI, University of Reunion Island, Saint-Clotilde, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Frédéric Tangy

    Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Anastassia V Komarova

    Unité de Génomique Virale et Vaccination, Institut Pasteur, Paris, France
    For correspondence
    stasy@pasteur.fr
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Xuetao Cao, Zhejiang University School of Medicine, China

Version history

  1. Received: September 1, 2015
  2. Accepted: March 24, 2016
  3. Accepted Manuscript published: March 24, 2016 (version 1)
  4. Version of Record published: April 20, 2016 (version 2)

Copyright

© 2016, Sanchez David et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,302
    views
  • 1,058
    downloads
  • 76
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Raul Y Sanchez David
  2. Chantal Combredet
  3. Odile Sismeiro
  4. Marie-Agnès Dillies
  5. Bernd Jagla
  6. Jean-Yves Coppée
  7. Marie Mura
  8. Mathilde Guerbois Galla
  9. Philippe Despres
  10. Frédéric Tangy
  11. Anastassia V Komarova
(2016)
Comparative analysis of viral RNA signatures on different RIG-I-like receptors
eLife 5:e11275.
https://doi.org/10.7554/eLife.11275

Share this article

https://doi.org/10.7554/eLife.11275

Further reading

    1. Cancer Biology
    2. Immunology and Inflammation
    Nicholas J Mullen, Surendra K Shukla ... Pankaj K Singh
    Research Article

    Pyrimidine nucleotide biosynthesis is a druggable metabolic dependency of cancer cells, and chemotherapy agents targeting pyrimidine metabolism are the backbone of treatment for many cancers. Dihydroorotate dehydrogenase (DHODH) is an essential enzyme in the de novo pyrimidine biosynthesis pathway that can be targeted by clinically approved inhibitors. However, despite robust preclinical anticancer efficacy, DHODH inhibitors have shown limited single-agent activity in phase 1 and 2 clinical trials. Therefore, novel combination therapy strategies are necessary to realize the potential of these drugs. To search for therapeutic vulnerabilities induced by DHODH inhibition, we examined gene expression changes in cancer cells treated with the potent and selective DHODH inhibitor brequinar (BQ). This revealed that BQ treatment causes upregulation of antigen presentation pathway genes and cell surface MHC class I expression. Mechanistic studies showed that this effect is (1) strictly dependent on pyrimidine nucleotide depletion, (2) independent of canonical antigen presentation pathway transcriptional regulators, and (3) mediated by RNA polymerase II elongation control by positive transcription elongation factor B (P-TEFb). Furthermore, BQ showed impressive single-agent efficacy in the immunocompetent B16F10 melanoma model, and combination treatment with BQ and dual immune checkpoint blockade (anti-CTLA-4 plus anti-PD-1) significantly prolonged mouse survival compared to either therapy alone. Our results have important implications for the clinical development of DHODH inhibitors and provide a rationale for combination therapy with BQ and immune checkpoint blockade.

    1. Immunology and Inflammation
    Hyereen Kang, Seong Woo Choi ... Myung-Shik Lee
    Research Article

    We studied lysosomal Ca2+ in inflammasome. Lipopolysaccharide (LPS) + palmitic acid (PA) decreased lysosomal Ca2+ ([Ca2+]Lys) and increased [Ca2+]i through mitochondrial ROS, which was suppressed in Trpm2-KO macrophages. Inflammasome activation and metabolic inflammation in adipose tissue of high-fat diet (HFD)-fed mice were ameliorated by Trpm2 KO. ER→lysosome Ca2+ refilling occurred after lysosomal Ca2+ release whose blockade attenuated LPS + PA-induced inflammasome. Subsequently, store-operated Ca2+entry (SOCE) was activated whose inhibition suppressed inflammasome. SOCE was coupled with K+ efflux whose inhibition reduced ER Ca2+ content ([Ca2+]ER) and impaired [Ca2+]Lys recovery. LPS + PA activated KCa3.1 channel, a Ca2+-activated K+ channel. Inhibitors of KCa3.1 channel or Kcnn4 KO reduced [Ca2+]ER, attenuated increase of [Ca2+]i or inflammasome activation by LPS + PA, and ameliorated HFD-induced inflammasome or metabolic inflammation. Lysosomal Ca2+ release induced delayed JNK and ASC phosphorylation through CAMKII-ASK1. These results suggest a novel role of lysosomal Ca2+ release sustained by ERlysosome Ca2+ refilling and K+ efflux through KCa3.1 channel in inflammasome activation and metabolic inflammation.